Fitness trackers improving as heart rate monitors, but terrible at tracking calories

When it comes to tracking calories, wearables like Apple Watch and Fitbit often provide very inaccurate information, according to Stanford University researchers.

The study, published in the Journal of Personalized Medicine, evaluated seven devices (Apple Watch, Basis Peak, Fitbit Surge, Microsoft Band, Mio Alpha 2, PulseOn and Samsung Gear S2) using 60 volunteers on treadmills and stationary cycles. Rather than comparing the devices to each other, researchers compared their accuracy to the U.S. Food and Drug Administration's standards for medical devices.

What they found is some devices, particularly Apple Watch, are getting more accurate at tracking a user’s heart rate. For measuring calories, however, the data provided was way off—the most accurate device had an average error rate of 27 percent.

“For a lay user, in a non-medical setting, we want to keep that error under 10 percent,” said study author and Stanford graduate student Anna Shcherbina, PhD.

Her best guess as to why energy expenditure measurements were so incorrect would be the variables affecting each device’s algorithm, as each user’s fitness level, height and weight could affect those results.

The take-home message for both users and practicing physicians, according to co-author Euan Ashley, DPhil, is the heart rate measurements from consumer-level wearables are largely reliable, which goes against results from an earlier study released by the Cleveland Clinic.

“The heart rate measurements performed far better than we expected,” Ashley said, “but the energy expenditure measures were way off the mark.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.